1e
19
1
49
2
2
18
1b
1d
18
32
63
1d
2 29
1d
25
Matthew P Connor, MD
88
63
Assistant Professor of Clinical Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
3
2
4
b
1f
54
Perelman Center for Advanced Medicine
1f 3400 Civic Center Blvd
34 12 South Pavilion
Philadelphia, PA 19104
26
1f 3400 Civic Center Blvd
34 12 South Pavilion
Philadelphia, PA 19104
2e
Office: 267-624-4512
32 Fax: 215-615-5888
24
ab
12
32 Fax: 215-615-5888
24
13
Education:
21 7 BS 15 (Biology ) c
28 Boston College , 2011.
21 7 MD 16 (Medicine ) c
4c Roaslind Franklin University of Medicine & Science , 2018.
c
3
3
3
3
8d
Permanent link21 7 BS 15 (Biology ) c
28 Boston College , 2011.
21 7 MD 16 (Medicine ) c
4c Roaslind Franklin University of Medicine & Science , 2018.
c
2 29
21
1e
1d
24
5e
26 29
27
Description of Clinical Expertise
9c Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Immune Effector Cell Therapies, Allogeneic Stem Cell Transplantation26 29
23
3f2 Kopmar NE, Gooley TA, Roloff GW, Zhang A, Aldoss I, Lin C, Bezerra E, Muhsen I, Jeyakumar N, Dykes KC, O'Connor T, Tang K, Chen EC, Connor M, Frey NV, Gordillo CA, Hilal T, Al Darobi AH, Hoeg RT, Irizarry Gatell VM, Valtis YK, Jackson CW, Kota VK, Koura D, Boccucci J, Guzowski C, Kumaran MV, Ladha A, Lee CJ, Majhail NS, Malik SA, Mathews J, Miller K, Moore J, Mountjoy L, O'Dwyer KM, Odstrcil Bobillo S, Oliai CH, Oluwole OO, Pradeep R, Othman T, Ramakrishnan A, Reshef R, Sasine J, Vasu S, Schwartz M, Shaughnessy P, Stefan M, Stock W, Sutherland KC, Tan V, Solh MM, Tracy S, Luskin M, Logan AC, Leonard JT, Hill L, Tsai SB, Advani AS, Ulrickson M, Bachanova V, Dholaria B, Park JH, Battiwalla M, Faramand R, Shah BD, Yaghmour G, Muffly LS, Cassaday RD: Toxicity of Brexucabtagene Autoleucel as a Standard Therapy for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Blood Immunol Cell Ther(100028), December 2025.
102 Logan A, Yalniz F, Zhang A, Miller K, Sutherland K, Jeyakumar N, Srinagesh H, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Sasine J, Hill L, Muhsen I, Advani A, Aldoss I, Othman T, Sandhu K, Reshef R, 366 Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Valtis Y, Vasu S, Bezerra E, Wang E, Leonard J, Tan V, O'Dwyer K, Moore J, McCauley R, Majhail N, Mountjoy L, Ramakrishnan A, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Roloff G, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Daunov M, Byrd K, Bachanova V, Tracy S, Grover P, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Faramand R, Muffly L: Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world. Blood 146(Supplement 1): 516, November 2025.
231 Connor M, Hwang W, Gill S, Perl A, Jordan Bruno X, Hossain N, Lai C, Loren A, Luger S, Matthews A, McCurdy S, Munshi P, Pratz K, Cervini A, McConville J, Shea J, Tongue C, Difilippo H, Kesselman J, Marshall A, Four M, Christensen S, Gonzalez V, Jadlowsky J, Plesa G, Siegel D, Leskowitz R, Fraietta J, Levine B, Porter D, Hexner E, June C, Svoboda J, Frey N: IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia. Blood 146(Supplement 1): 812, November 2025.
413 McCauley R, Zhang A, Kota V, Boccucci J, Grunwald M, Ulrickson M, Hill L, Muhsen I, Sasine J, Advani A, Aldoss I, Sandhu K, Reshef R, Luskin M, Lin C, Cassaday R, Kopmar N, Solh M, Odstrcil Bobillo S, Tsai S, Hilal T, Shah B, Faramand R, Park J, Valtis Y, Othman T, Vasu S, Bezerra E, Leonard J, Tan V, O'Dwyer K, Moore J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Al-Darobi A, Chen E, Lee C, O'Connor T, Dholaria B, Bachanova V, Tracy S, Srinagesh H, Miller K, Sutherland K, Majhail N, Mountjoy L, Malik S, Ramakrishnan A, Shaughnessy P, Mathews J, Wang E, Battiwalla M, Roloff G, Muffly L: CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel. Blood 146(Supplement 1): 2396, November 2025.
46f Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, Miller K, Zhang A, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Hill L, Muhsen I, Sasine J, Advani A, Sandhu K, Reshef R, Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Vasu S, Bezerra E, O'Dwyer K, Moore J, Wang E, McCauley R, Majhail N, Ramakrishnan A, Mountjoy L, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Srinagesh H, Sutherland K, Jamy O, Mohty R, Kumaran M, Hoeg R, Oliai C, Lill G, Stock W, Schwartz M, Othman T, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Bachanova V, Tracy S, Grover P, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Frey N, Muffly L, Shah B, Aldoss, I: KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). Blood 146(Supplement 1): 3365, November 2025.
23d Svoboda J, Schuster S, Porter D, Cook M, Nasta SD, Landsburg D, Barta S, Ruella M, Chong E, Carter J, Thomas C, Tomasulo E, Frey N, Connor M, Shea J, Cervini A, McConville J, Tongue C, Four M, Marshall A, Hwang W, Leskowitz R, Gonzalez V, Christensen S, Plesa G, Siegel D, Jadlowsky J, Fraietta J, Levine B, Hexner E, June C: IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure. Blood 146(Supplement 1): 2394, November 2025.
336 Valtis Y, Sandhu K, Faramand R, Zhang A, Miller K, Hill L, Muhsen I, Othman T, Luskin M, Chen E, Oliai C, Lill G, Cassaday R, Kopmar N, Logan A, Connor M, Hilal T, Park J, Solh M, Guzowski C, Leonard J, Tan V, Jeyakumar N, Srinagesh H, Kumaran M, Hoeg R, Koura D, Dykes K, Stock W, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, O'Dwyer K, Moore J, Ulrickson M, Al-Darobi A, Byrd K, Tsai S, O'Connor T, Wang E, McCauley R, Jamy O, Mohty R, Roloff G, Sutherland K, Aldoss I, Shah B, Muffly L, Frey N: Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis. Blood 146(Supplement 1): 2715, November 2025.
3b2 Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Bobillo SO, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH, Nair M, Ulrickson M, Ahmed M, Othman T, Bacani S, Stefan M, Luskin M, Cassaday R, O'Connor T, Guzowski C, Gordillo L, Vasu S, Majhail N, Malik S, Oliai C, Koura D, Stock W, Bachanova V, O'Dwyer K, Lee C, Yaghmour G, Oluwole O: CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood Adv In Press, October 2025.
3c2 O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B: The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant Online ahead of print, Aug 2025.
2c
7
1d
1f
Selected Publications
d3 Connor MP, Barsouk A, Elghawy O, Lai C: Advancements in targeted therapies for acute myeloid leukemia. Curr Opin Pharmacol 87, April 2026.3f2 Kopmar NE, Gooley TA, Roloff GW, Zhang A, Aldoss I, Lin C, Bezerra E, Muhsen I, Jeyakumar N, Dykes KC, O'Connor T, Tang K, Chen EC, Connor M, Frey NV, Gordillo CA, Hilal T, Al Darobi AH, Hoeg RT, Irizarry Gatell VM, Valtis YK, Jackson CW, Kota VK, Koura D, Boccucci J, Guzowski C, Kumaran MV, Ladha A, Lee CJ, Majhail NS, Malik SA, Mathews J, Miller K, Moore J, Mountjoy L, O'Dwyer KM, Odstrcil Bobillo S, Oliai CH, Oluwole OO, Pradeep R, Othman T, Ramakrishnan A, Reshef R, Sasine J, Vasu S, Schwartz M, Shaughnessy P, Stefan M, Stock W, Sutherland KC, Tan V, Solh MM, Tracy S, Luskin M, Logan AC, Leonard JT, Hill L, Tsai SB, Advani AS, Ulrickson M, Bachanova V, Dholaria B, Park JH, Battiwalla M, Faramand R, Shah BD, Yaghmour G, Muffly LS, Cassaday RD: Toxicity of Brexucabtagene Autoleucel as a Standard Therapy for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Blood Immunol Cell Ther(100028), December 2025.
102 Logan A, Yalniz F, Zhang A, Miller K, Sutherland K, Jeyakumar N, Srinagesh H, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Sasine J, Hill L, Muhsen I, Advani A, Aldoss I, Othman T, Sandhu K, Reshef R, 366 Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Valtis Y, Vasu S, Bezerra E, Wang E, Leonard J, Tan V, O'Dwyer K, Moore J, McCauley R, Majhail N, Mountjoy L, Ramakrishnan A, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Roloff G, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Daunov M, Byrd K, Bachanova V, Tracy S, Grover P, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Faramand R, Muffly L: Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world. Blood 146(Supplement 1): 516, November 2025.
231 Connor M, Hwang W, Gill S, Perl A, Jordan Bruno X, Hossain N, Lai C, Loren A, Luger S, Matthews A, McCurdy S, Munshi P, Pratz K, Cervini A, McConville J, Shea J, Tongue C, Difilippo H, Kesselman J, Marshall A, Four M, Christensen S, Gonzalez V, Jadlowsky J, Plesa G, Siegel D, Leskowitz R, Fraietta J, Levine B, Porter D, Hexner E, June C, Svoboda J, Frey N: IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia. Blood 146(Supplement 1): 812, November 2025.
413 McCauley R, Zhang A, Kota V, Boccucci J, Grunwald M, Ulrickson M, Hill L, Muhsen I, Sasine J, Advani A, Aldoss I, Sandhu K, Reshef R, Luskin M, Lin C, Cassaday R, Kopmar N, Solh M, Odstrcil Bobillo S, Tsai S, Hilal T, Shah B, Faramand R, Park J, Valtis Y, Othman T, Vasu S, Bezerra E, Leonard J, Tan V, O'Dwyer K, Moore J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Al-Darobi A, Chen E, Lee C, O'Connor T, Dholaria B, Bachanova V, Tracy S, Srinagesh H, Miller K, Sutherland K, Majhail N, Mountjoy L, Malik S, Ramakrishnan A, Shaughnessy P, Mathews J, Wang E, Battiwalla M, Roloff G, Muffly L: CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel. Blood 146(Supplement 1): 2396, November 2025.
46f Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, Miller K, Zhang A, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Hill L, Muhsen I, Sasine J, Advani A, Sandhu K, Reshef R, Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Vasu S, Bezerra E, O'Dwyer K, Moore J, Wang E, McCauley R, Majhail N, Ramakrishnan A, Mountjoy L, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Srinagesh H, Sutherland K, Jamy O, Mohty R, Kumaran M, Hoeg R, Oliai C, Lill G, Stock W, Schwartz M, Othman T, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Bachanova V, Tracy S, Grover P, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Frey N, Muffly L, Shah B, Aldoss, I: KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel). Blood 146(Supplement 1): 3365, November 2025.
23d Svoboda J, Schuster S, Porter D, Cook M, Nasta SD, Landsburg D, Barta S, Ruella M, Chong E, Carter J, Thomas C, Tomasulo E, Frey N, Connor M, Shea J, Cervini A, McConville J, Tongue C, Four M, Marshall A, Hwang W, Leskowitz R, Gonzalez V, Christensen S, Plesa G, Siegel D, Jadlowsky J, Fraietta J, Levine B, Hexner E, June C: IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure. Blood 146(Supplement 1): 2394, November 2025.
336 Valtis Y, Sandhu K, Faramand R, Zhang A, Miller K, Hill L, Muhsen I, Othman T, Luskin M, Chen E, Oliai C, Lill G, Cassaday R, Kopmar N, Logan A, Connor M, Hilal T, Park J, Solh M, Guzowski C, Leonard J, Tan V, Jeyakumar N, Srinagesh H, Kumaran M, Hoeg R, Koura D, Dykes K, Stock W, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, O'Dwyer K, Moore J, Ulrickson M, Al-Darobi A, Byrd K, Tsai S, O'Connor T, Wang E, McCauley R, Jamy O, Mohty R, Roloff G, Sutherland K, Aldoss I, Shah B, Muffly L, Frey N: Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis. Blood 146(Supplement 1): 2715, November 2025.
3b2 Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Bobillo SO, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH, Nair M, Ulrickson M, Ahmed M, Othman T, Bacani S, Stefan M, Luskin M, Cassaday R, O'Connor T, Guzowski C, Gordillo L, Vasu S, Majhail N, Malik S, Oliai C, Koura D, Stock W, Bachanova V, O'Dwyer K, Lee C, Yaghmour G, Oluwole O: CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood Adv In Press, October 2025.
3c2 O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B: The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant Online ahead of print, Aug 2025.
2c